[ad_1]
More and more adults with type 1 diabetes, including pregnant women and children, will benefit from expanded free federal government access to blood glucose monitoring devices.
The investment of more than $ 100,000 million in additional funding over the next four years will make the devices available to more than 37,000 eligible individuals with this disease.
Starting March 1 next year, as part of the National Diabetes Management Program, the application criteria for fully subsidized continuous glucose monitoring devices will be extended to pregnant, lactating and current women of pregnancy, to persons aged 21 years or older who have a high clinical need status, such as recurrent episodes of severe hypoglycemia, as well as children and adolescents with conditions similar to diabetes-type 1 requiring insulin. This includes diabetes related to cystic fibrosis or neonatal diabetes.
This initiative is expected to save up to $ 7,000 a year.
Type 1 diabetes is an autoimmune disease that attacks a person's ability to produce insulin. People have to watch their blood glucose day and night.
The devices can continuously monitor a person's blood glucose and issue alerts if their fall is too low.
It is a sensor, usually attached to the stomach, which monitors the levels and whose alarm can alert people or their caregivers in case of falling levels.
The free FreeStyle Flash Blood Glucose Monitoring System is one of the devices added to the system by the government.
The device has a sensor located on the arm that monitors the glucose levels and sends the measurements to the user's mobile phone or diabetes management device.
When a patient pbades his phone or device in front of the sensor, he records his glucose level.
Regular endurance athlete and ultra-marathon competitor, he uses the application to check his blood sugar level.
"It's awesome. It's one less thing that I have to carry, "he said. "It's pretty accurate."
The government will work with Diabetes Australia and diabetes experts to implement the expanded program and finalize the clinical criteria.
[ad_2]
Source link
